AU2007207675B2 - Inhibition of inflammatory cytokine production with tanshinones - Google Patents

Inhibition of inflammatory cytokine production with tanshinones Download PDF

Info

Publication number
AU2007207675B2
AU2007207675B2 AU2007207675A AU2007207675A AU2007207675B2 AU 2007207675 B2 AU2007207675 B2 AU 2007207675B2 AU 2007207675 A AU2007207675 A AU 2007207675A AU 2007207675 A AU2007207675 A AU 2007207675A AU 2007207675 B2 AU2007207675 B2 AU 2007207675B2
Authority
AU
Australia
Prior art keywords
tanshinone
sepsis
mammal
release
tsniia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007207675A
Other languages
English (en)
Other versions
AU2007207675A1 (en
Inventor
Dazhi Chen
Andrew E. Sama
Haichao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Feinstein Institutes for Medical Research
Original Assignee
The Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Feinstein Institutes for Medical Research filed Critical The Feinstein Institutes for Medical Research
Publication of AU2007207675A1 publication Critical patent/AU2007207675A1/en
Application granted granted Critical
Publication of AU2007207675B2 publication Critical patent/AU2007207675B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
AU2007207675A 2006-01-13 2007-01-12 Inhibition of inflammatory cytokine production with tanshinones Ceased AU2007207675B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75923706P 2006-01-13 2006-01-13
US60/759,237 2006-01-13
PCT/US2007/000945 WO2007084419A2 (en) 2006-01-13 2007-01-12 Inhibition of inflammatory cytokine production with tanshinones

Publications (2)

Publication Number Publication Date
AU2007207675A1 AU2007207675A1 (en) 2007-07-26
AU2007207675B2 true AU2007207675B2 (en) 2013-01-31

Family

ID=38288155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007207675A Ceased AU2007207675B2 (en) 2006-01-13 2007-01-12 Inhibition of inflammatory cytokine production with tanshinones

Country Status (7)

Country Link
US (1) US8513227B2 (cg-RX-API-DMAC7.html)
EP (1) EP1981489B1 (cg-RX-API-DMAC7.html)
JP (1) JP5247469B2 (cg-RX-API-DMAC7.html)
CN (1) CN101394860B (cg-RX-API-DMAC7.html)
AU (1) AU2007207675B2 (cg-RX-API-DMAC7.html)
CA (1) CA2636909A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007084419A2 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101327249B (zh) * 2007-06-21 2012-07-18 天津天士力制药股份有限公司 二羟基苯基乳酸在制备治疗败血症的药物中的应用
WO2010088786A1 (zh) * 2009-02-06 2010-08-12 Lin Xiuying 具有cox-2和免疫活性的草药组合物及其制备方法
CN106367478A (zh) 2009-12-22 2017-02-01 雅芳产品公司 桩蛋白刺激组合物及其化妆品用途
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
DK2365332T3 (da) * 2010-03-10 2013-08-26 Pasteur Institut HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
CN102949399B (zh) * 2011-08-23 2016-02-24 上海中医药大学附属岳阳中西医结合医院 丹参酮iia在制备抑制角质形成细胞增殖疾病药中的应用
KR101612051B1 (ko) * 2011-12-20 2016-04-27 한국생명공학연구원 단삼 추출물을 포함하는 코로나 바이러스 감염의 예방 또는 치료용 조성물
KR101400900B1 (ko) * 2012-01-26 2014-05-29 한국생명공학연구원 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물
CN102670768A (zh) * 2012-05-15 2012-09-19 宋协勘 一种治疗急性阑尾炎的中药
CN102824349A (zh) * 2012-09-14 2012-12-19 广东省中医院 丹参酮ⅱa在制备治疗银屑病药物中的应用
CN102973575A (zh) * 2012-11-23 2013-03-20 广东省中医院 隐丹参酮在制备治疗银屑病药物中的应用
CN103006549B (zh) * 2012-12-05 2015-04-15 广东宏远集团药业有限公司 采用助溶消泡溶剂制备丹参酮iia磺酸钠制剂的方法
CN103040837A (zh) * 2013-01-13 2013-04-17 广东宏盈科技有限公司 一种眼科外用降眼压药物
GB201312205D0 (en) * 2013-07-08 2013-08-21 Univ Leuven Kath Anticonvulsant activity of dan shen extracting compounds
KR20170006030A (ko) * 2015-07-07 2017-01-17 재단법인 진안홍삼연구소 크립토탄시논을 유효성분으로 포함하는 구강세균 독성에 의한 염증을 예방, 개선 또는 치료하는 조성물
CN105168222A (zh) * 2015-07-23 2015-12-23 南京赋海澳赛医药科技有限公司 组合物及其在抗鼻炎药物中的应用
WO2017070421A1 (en) * 2015-10-22 2017-04-27 The Feinstein Institute For Medical Research Use of dermcidin in sterile inflammatory conditions
CN108264515B (zh) * 2017-01-04 2021-01-12 中国科学院上海药物研究所 一类苯并[def]咔唑类化合物及其制备方法和应用
CN106924740A (zh) * 2017-03-15 2017-07-07 河南科技大学 一种治疗急性肺损伤的药物组合物
CN106963776A (zh) * 2017-04-26 2017-07-21 上海市疾病预防控制中心 一种化合物在制备以组织蛋白酶k为靶标的疾病药中的应用
CN108785314A (zh) * 2017-05-03 2018-11-13 阎永平 用于治疗和预防酒精性肝病的药物及其组合物
PL3773537T3 (pl) 2018-04-19 2022-05-23 Tvardi Therapeutics, Inc. Inhibitory stat3
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
CN108837001A (zh) * 2018-07-20 2018-11-20 深圳市博奥生物科技有限公司 一种三七丹参片及其制备方法
CN108685981A (zh) * 2018-07-20 2018-10-23 深圳市博奥生物科技有限公司 一种三七丹参胶囊及其制备方法
EP3873458A4 (en) * 2018-11-02 2022-07-06 University of Maryland, Baltimore TYPE 3 SECRETION SYSTEM INHIBITORS AND ANTIBIOTIC THERAPY
CN115052584B (zh) 2020-01-24 2024-08-23 特维迪疗法公司 治疗性化合物及其制剂和用途
CN111166754A (zh) * 2020-02-25 2020-05-19 上海市第六人民医院 隐丹参酮在制备防治恶病质骨骼肌萎缩药物中的应用
CN111214467A (zh) * 2020-03-05 2020-06-02 南京巴傲得生物科技有限公司 吲哚布洛芬在抵抗hmgb1促炎活性中的应用
CN113679726B (zh) * 2020-05-18 2025-01-10 上海科技大学 丹参提取物和醌类化合物在抗冠状病毒中的应用
CN116098060A (zh) * 2020-06-10 2023-05-12 甘肃省农业科学院经济作物与啤酒原料研究所(甘肃省农业科学院中药材研究所) 一种当归组培苗生根培养方法
CN115025103A (zh) * 2021-03-04 2022-09-09 上海上药第一生化药业有限公司 丹参酮iia磺酸钠在制备药物中的应用
CN113005130B (zh) * 2021-03-18 2022-07-08 上海辰山植物园 丹参酮ⅱa合酶基因及应用
AU2023292912A1 (en) 2022-06-15 2025-01-16 Tvardi Operating Company, Inc. Prodrugs of stat3 inhibitors
CN117986316A (zh) * 2022-11-02 2024-05-07 广州中大南沙科技创新产业园有限公司 丹参中总丹参酮的提取方法及其应用
CN117442626A (zh) * 2023-09-22 2024-01-26 浙江大学绍兴研究院 隐丹参酮在防治人巨细胞病毒感染中的新用途
CN119950521A (zh) * 2025-01-14 2025-05-09 浙江工业大学 丹参酮i在制备治疗艾滋病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830077B2 (ja) * 1987-04-24 1996-03-27 晟 八木 虚血性疾患治療剤
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
CN1251718C (zh) * 2003-05-13 2006-04-19 天津红日药业股份有限公司 一种预防、治疗脓毒症的中药复方制剂及其制备方法
WO2005063232A1 (en) * 2003-12-30 2005-07-14 Md Bioalpha Co., Ltd. Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
KR100725839B1 (ko) * 2005-10-06 2007-12-11 일성신약주식회사 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kyoko Takahashi et al, Biochemical Pharmacology (2002), 64, pages 745 - 750 *
Seon-Il Jang et al, Planta Medica, (2003) 69, 11, pp1057 - 1059. *

Also Published As

Publication number Publication date
EP1981489A4 (en) 2010-07-28
WO2007084419A2 (en) 2007-07-26
CN101394860A (zh) 2009-03-25
EP1981489A2 (en) 2008-10-22
JP5247469B2 (ja) 2013-07-24
WO2007084419A3 (en) 2008-10-09
AU2007207675A1 (en) 2007-07-26
EP1981489B1 (en) 2013-05-01
US8513227B2 (en) 2013-08-20
CN101394860B (zh) 2013-05-29
JP2009523730A (ja) 2009-06-25
US20090221542A1 (en) 2009-09-03
CA2636909A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
EP1981489B1 (en) Inhibition of inflammatory cytokine production with tanshinones
Yu et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
US12071414B2 (en) Apelin receptor agonists and methods of use thereof
CA2566445C (en) Methods related to the treatment of neurodegenerative and inflammatory conditions
Wu et al. Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity
TW201121956A (en) Use of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistant cancer
US11376233B2 (en) Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss
CN110790739A (zh) 用于治疗神经系统疾病的化合物及其应用
JP2017502056A (ja) 肝障害の治療方法
CA3135943A1 (en) Novel compound and method for preventing or treating of respiratory disease comprising the same as an active ingredient
KR102600785B1 (ko) 페놀산 유도체를 유효성분으로 포함하는 식욕 억제용 조성물
JP5288532B2 (ja) セスキテルペンラクトンを含有する医薬組成物
CN108368043A (zh) 用于治疗及/或预防纤维化疾病的吲哚啉衍生物
TW200536549A (en) Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
KR20150083353A (ko) 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물
TW201904579A (zh) Mcl-1抑制劑與血液癌症標準療法之組合,其用途及醫藥組合物
CN109939116A (zh) Rock2抑制剂在制备药物中的用途
Malik Doxorubicin-induced cardiomyopathy: role of endoplasmic reticulum stress
CN114159427B (zh) 一种包含安卓幸醇的组合物用于制备抑制肝癌细胞或肝癌干细胞生长的药物的用途
Hashioka et al. Pyrazole compound 2-MBAPA as a novel inhibitor of microglial activation and neurotoxicity in vitro and in vivo
CN119950503A (zh) 生物活性植物化学物
KR20240169284A (ko) AhR-매개 질환의 예방, 개선 또는 치료용 약학적 조성물
JP2020516696A (ja) 多嚢胞性卵巣症候群を治療するためのイソフムロン及びその誘導体の使用
Balbi Group I metabotropic glutamatergic receptors regulating glutamate release and microglia phenotype in a murine model of amyotrophic lateral sclerosis
TW202210073A (zh) 一種包含安卓幸醇之組合物用於製備抑制肝癌細胞或肝癌幹細胞生長之藥物的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired